Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 27

Sort by

Sort Order Select

Journal Articles

Proteomic Characterisation of the Plasma Proteome in Extramedullary Multiple Myeloma Identifies Potential Prognostic Biomarkers

Katie Dunphy, Despina Bazou, Paul Dowling, Peter O'Gorman

Blood (2022) 140 (Supplement 1): 10058–10059.

https://doi.org/10.1182/blood-2022-159935

Published: 2022

Journal Articles

Targeted Metabolomics Approach Identifies Alterations in the Plasma Metabolome of Multiple Myeloma Patients with and without Extramedullary Spread

Katie Dunphy, Despina Bazou, Paul Dowling, Peter O'Gorman

Blood (2022) 140 (Supplement 1): 4328–4329.

https://doi.org/10.1182/blood-2022-160198

Published: 2022

Journal Articles

Phosphoproteomic Analysis of Primary Myeloma Patient Samples Identifies Distinct Phosphorylation Signatures Correlating with Chemo-Sensitivity Profiles in an Ex Vivo Drug Sensitivity Testing Platform

Katie Dunphy, Paul Dowling, Juho J. Miettinen, Caroline A. Heckman, Paula Meleady, Michael Henry, Despina Bazou, Peter O'Gorman

Blood (2021) 138 (Supplement 1): 2666.

https://doi.org/10.1182/blood-2021-148382

Published: 2021

Journal Articles

Characterisation of the Tumour Proteome in Primary Extramedullary Multiple Myeloma Identifies Key Proteins Associated with Transendothelial Migration

Katie Dunphy, Despina Bazou, Michael Henry, Paula Meleady, Paul Dowling, Peter O'Gorman

Blood (2021) 138 (Supplement 1): 2665.

https://doi.org/10.1182/blood-2021-152676

Published: 2021

Journal Articles

Examining the Usefulness of the Charlson Comorbidity Index to Predict Early Mortality in Patients with Acute Myeloid Leukaemia

Mohamed Bakri Mohamed, Seán R Millar, Vitaliy Mykytiv, Rose McMorrow, Conan Donnelly, Paul M Walsh, Eamonn O'Leary, Nina Orfali, Philip Murphy, Paul V. Browne, John Quinn, Peter O'Gorman, Ruth Clifford, Ezzat El Hassadi, Oonagh Gilligan, Janusz Krawczyk, Michael E. O'Dwyer, Eva Szegezdi, Mary R Cahill

Blood (2021) 138 (Supplement 1): 1218.

https://doi.org/10.1182/blood-2021-149832

Published: 2021

Journal Articles

Defibrotide for the Treatment of Endotheliitis Complicating Sars-Cov-2 Infection: Rationale and Ongoing Studies As Part of the International Defacovid Study Group

Blood (2020) 136 (Supplement 1): 6–8.

https://doi.org/10.1182/blood-2020-141872

Published: 2020

Journal Articles

Multi-Parametric Single Cell Profiling Defines Distinct Drug Responses in Healthy Hematological Cell Lineages That Are Retained in Corresponding Malignant Cell Types

Muntasir M Majumder, MSc, BPharm, Maija Leppä, MSc(Tech), Monica Hellesoy, PhD, Paul Dowling, BSc, PhD, Alina Malyutina, Despina Bazou, BSc, MSc, PhD, Emma Irene Andersson, MSc, Alun Parsons, Jing Tang, PhD, Olli Kallioniemi, MD PhD, Satu Mustjoki, MDPhD, Peter O'Gorman, MD PhD FRCP, FRCPath, Krister Wennerberg, PhD, Kimmo Porkka, MD PhD, Bjorn Gjertsen, MD PhD, Caroline A Heckman, PhD

Blood (2018) 132 (Supplement 1): 264.

https://doi.org/10.1182/blood-2018-99-118242

Published: 2018

Journal Articles

Combining Next Generation Proteomics Platforms with Drug Sensitivity Resistance Testing AllowsÂ Identification of Physiologically Distinct Sub-ClonesÂ That Can Inform Therapeutic and Drug Development Strategies

Despina Bazou, BSc, MSc, PhD, Muntasir M Majumder, MSc, BPharm, Ciara Tierney, BSc, Sinead O'Rourke, BSc, Pekka Anttila, MD, Raija Helena Silvennoinen, MD PhD, Caroline A Heckman, PhD, Paul Dowling, BSc, PhD, Peter O'Gorman, MD PhD FRCP, FRCPath

Blood (2018) 132 (Supplement 1): 1901.

https://doi.org/10.1182/blood-2018-99-115910

Published: 2018

Journal Articles

A Phase II Study of the Efficacy and Safety of Lenalidomide, Subcutaneous Bortezomib and Dexamethasone (RVD) Combination Therapy for Patients with Newly Diagnosed Multiple Myeloma: Promising Activity and Manageable Toxicity, Including in High Risk Disease

Blood (2018) 132 (Supplement 1): 1981.

https://doi.org/10.1182/blood-2018-99-116280

Published: 2018

Journal Articles

Saliva-Omics in Plasma Cell Disorders — Proof of Concept and Potential As a Non-Invasive Tool for Monitoring Disease Burden and MRD Status

Ciara Tierney, BSc, Despina Bazou, BSc, MSc, PhD, Giao Le, BA (Hons), MB BCh, MRCPI, Paul Dowling, BSc, PhD, Peter O'Gorman, MD PhD FRCP, FRCPath

Blood (2018) 132 (Supplement 1): 3177.

https://doi.org/10.1182/blood-2018-99-110166

Published: 2018

Journal Articles

Blocking HDAC3 in Bone Marrow Stromal Cells Has Direct Anti-Multiple Myeloma Effect and Modulates T Cell Function

Matthew Ho, Jiye Liu, PhD, Alireza Kalbasi, PharmD, Takeshi Harada, MDPhD, Teru Hideshima, MD PhD, Paul Dowling, BSc, PhD, Yu-Tzu Tai, PhD, Li Zhang, MD, Kenneth Wen, BS, Ralph Mazitschek, Amanda McCann, Kenneth C Anderson, MD, Peter O'Gorman, MD PhD FRCP, FRCPath, Giada Bianchi, MD

Blood (2017) 130 (Supplement 1): 4429.

https://doi.org/10.1182/blood.V130.Suppl_1.4429.4429

Published: 2017

Journal Articles

A Phase II Multi-Center Study of Lenalidomide, Subcutaneous Bortezomib and Dexamethasone (RsqVD) in Newly Diagnosed Multiple Myeloma - Ctrial-IE (ICORG) 13-17 Study

Blood (2016) 128 (22): 2117.

https://doi.org/10.1182/blood.V128.22.2117.2117

Published: 2016

Journal Articles

Examining the Impact of Altered Protein Expression and Ubiquitination Levels on the Development of Resistance to Proteasome Inhibitors Using Proteomics Analysis

Paul Dowling, Kay Reen Ting, Justine Meiller, Shane Kelly, Martin Clynes, Peter O'Gorman

Blood (2015) 126 (23): 4208.

https://doi.org/10.1182/blood.V126.23.4208.4208

Published: 2015

Journal Articles

N -Glycan Analysis of Polyclonal IgG from Patients with Multiple Myeloma Enables Classification of Stage Specific Pathologies

Stefan Mittermayr, PhD, Jonathan Bones, PhD, Giao N Le, MB, BCh, BAO, MRCP, Peter O'Gorman

Blood (2015) 126 (23): 1761.

https://doi.org/10.1182/blood.V126.23.1761.1761

Published: 2015

Journal Articles

Characterisation of Myeloma Paraprotein Glycosylation Reveals Functional Insights and Increased Sialylation of Residual Polyclonal Antibodies

Stefan Mittermayr, PhD, Jonathan Bones, PhD, Giao N Le, MB, BCh, BAO, MRCP, Peter O'Gorman

Blood (2015) 126 (23): 1775.

https://doi.org/10.1182/blood.V126.23.1775.1775

Published: 2015

Journal Articles

Clinical Characteristics, Treatment and Outcomes for Patients with Myelodysplastic Syndromes and Chromosome 5q Abnormalities in the Republic of Ireland

Su Wai Maung, MBBS, MRCP(UK), Cian McEllistrim, MRCPI, Amjad Hayat, MBBS, MRCP, FRCPath, PhD, Margaret Murray, FRCPath, Michael O'Dwyer, MD, Patrick Thornton, FRCPath, Emma Groarke, MRCPI, Denis O'Keeffe, MD MRCPath, Maeve Leahy, MD MRCPath, Aine Burke, MRCP,MD, Peter O'Gorman, Carmel Weldon, M.Sc, MRCPI, Gerard Crotty, MD FRCPath, Meegahage Ratnakanthi Perera, MDMRCPath,MBBS, Cathie Burke, RN, Johnny McHugh, FRCPath, Helen Enright, MD FRCPI, FRCPath, Ronan Desmond, MD FRCPath

Blood (2015) 126 (23): 5258.

https://doi.org/10.1182/blood.V126.23.5258.5258

Published: 2015

Journal Articles

Bone Turnover Biomarkers Are Useful In Monitoring Myeloma Bone Disease and As Early Predictor Biomarkers For Relapse Disease In Multiple Myeloma

Kay Reen Ting, MB Bch BAO, Abdul Hameed, MBBS, MRCP, Jennifer Brady, Paul Dowling, PhD, Colin Clarke, PhD, Justine Meiller, Constantine S. Mitsiades, MD, PhD, Paul G. Richardson, MD, Kenneth C. Anderson, MD, Martin Clynes, PhD, Peter O'Gorman, MD, PhD

Blood (2013) 122 (21): 1869.

https://doi.org/10.1182/blood.V122.21.1869.1869

Published: 2013

Journal Articles

Cells of the Osteoblast Lineage Confer Myeloma Cell Resistance to Established and Investigational Therapeutic Agents

Catriona A. Hayes, MD, Paul Dowling, PhD, Richard W.J. Groen, PhD, Douglas W. McMillin, PhD, Jake E. Delmore, Hannah M. Jacobs, Niels W.C.J. van de Donk, MD, PhD, Eugen Dhimolea, PhD, Paul G. Richardson, MD, Kenneth C. Anderson, MD, Martin Clynes, PhD, Peter O'Gorman, M.D., Constantine S. Mitsiades, MD, PhD

Blood (2012) 120 (21): 3995.

https://doi.org/10.1182/blood.V120.21.3995.3995

Published: 2012

Journal Articles

Eltrombopag Treatment of Thrombocytopenia in Advanced Myelodysplastic Syndromes and Acute Myeloid Leukemia: Results of the 8-Week Open-Label Part of an Ongoing Study

Moshe Mittelman, MD, Sarit Assouline, Evangelos Briasoulis, Arancha Alonso, MD, Regina Garcia Delgado, MD, Peter O'Gorman, M.D., Hyeoung Joon Kim, MD, PhD, Sung-Soo Yoon, MD, PhD, Andrey Zaritskey, Catherine M. Flynn, MD, MRCP, FRCPath, Yoo-Hong Min, María Diez-Campelo, Alexandr Myasnikov, Frank Mannino, Yasser Mostafa Kamel, Conrad Messam, Nicole L. Stone, PhD, Geoffrey W. Chan, MD

Blood (2012) 120 (21): 3822.

https://doi.org/10.1182/blood.V120.21.3822.3822

Published: 2012

Journal Articles

The Interaction of Bortezomib with P-Gp, MRP-1 and BCRP Drug Transporters: Implications for Therapeutic Applications of Bortezomib in Advanced Multiple Myeloma and Other Neoplasias.

Melissa G Ooi, M.D., Robert O'Connor, Ph.D, Jana Jakubikova, Ph.D, Justine Meiller, Diploma, in, Biochemistry, Degre, Steffen Klippel, Ph.D, Jake Delmore, Efstathios Kastritis, M.D, Douglas McMillin, Ph.D, Martin Clynes, Ph.D, Paul Richardson, M.D., Constantine S. Mitsiades, M.D., Ph.D, Peter O'Gorman, M.D., Kenneth C. Anderson, M.D.

Blood (2009) 114 (22): 1729.

https://doi.org/10.1182/blood.V114.22.1729.1729

Published: 2009

NARROW

Proteomic Characterisation of the Plasma Proteome in Extramedullary Multiple Myeloma Identifies Potential Prognostic Biomarkers

Targeted Metabolomics Approach Identifies Alterations in the Plasma Metabolome of Multiple Myeloma Patients with and without Extramedullary Spread

Phosphoproteomic Analysis of Primary Myeloma Patient Samples Identifies Distinct Phosphorylation Signatures Correlating with Chemo-Sensitivity Profiles in an Ex Vivo Drug Sensitivity Testing Platform

Characterisation of the Tumour Proteome in Primary Extramedullary Multiple Myeloma Identifies Key Proteins Associated with Transendothelial Migration

Examining the Usefulness of the Charlson Comorbidity Index to Predict Early Mortality in Patients with Acute Myeloid Leukaemia

Defibrotide for the Treatment of Endotheliitis Complicating Sars-Cov-2 Infection: Rationale and Ongoing Studies As Part of the International Defacovid Study Group

Multi-Parametric Single Cell Profiling Defines Distinct Drug Responses in Healthy Hematological Cell Lineages That Are Retained in Corresponding Malignant Cell Types

Combining Next Generation Proteomics Platforms with Drug Sensitivity Resistance Testing AllowsÂ Identification of Physiologically Distinct Sub-ClonesÂ That Can Inform Therapeutic and Drug Development Strategies

A Phase II Study of the Efficacy and Safety of Lenalidomide, Subcutaneous Bortezomib and Dexamethasone (RVD) Combination Therapy for Patients with Newly Diagnosed Multiple Myeloma: Promising Activity and Manageable Toxicity, Including in High Risk Disease

Saliva-Omics in Plasma Cell Disorders — Proof of Concept and Potential As a Non-Invasive Tool for Monitoring Disease Burden and MRD Status

Blocking HDAC3 in Bone Marrow Stromal Cells Has Direct Anti-Multiple Myeloma Effect and Modulates T Cell Function

A Phase II Multi-Center Study of Lenalidomide, Subcutaneous Bortezomib and Dexamethasone (RsqVD) in Newly Diagnosed Multiple Myeloma - Ctrial-IE (ICORG) 13-17 Study

Examining the Impact of Altered Protein Expression and Ubiquitination Levels on the Development of Resistance to Proteasome Inhibitors Using Proteomics Analysis

N -Glycan Analysis of Polyclonal IgG from Patients with Multiple Myeloma Enables Classification of Stage Specific Pathologies

Characterisation of Myeloma Paraprotein Glycosylation Reveals Functional Insights and Increased Sialylation of Residual Polyclonal Antibodies

Clinical Characteristics, Treatment and Outcomes for Patients with Myelodysplastic Syndromes and Chromosome 5q Abnormalities in the Republic of Ireland

Bone Turnover Biomarkers Are Useful In Monitoring Myeloma Bone Disease and As Early Predictor Biomarkers For Relapse Disease In Multiple Myeloma

Cells of the Osteoblast Lineage Confer Myeloma Cell Resistance to Established and Investigational Therapeutic Agents

Eltrombopag Treatment of Thrombocytopenia in Advanced Myelodysplastic Syndromes and Acute Myeloid Leukemia: Results of the 8-Week Open-Label Part of an Ongoing Study

The Interaction of Bortezomib with P-Gp, MRP-1 and BCRP Drug Transporters: Implications for Therapeutic Applications of Bortezomib in Advanced Multiple Myeloma and Other Neoplasias.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only